search
Back to results

Comparison of Two Antibiotic Prophylactic Protocols in Preterm Premature Rupture of the Membranes

Primary Purpose

Premature Rupture of Membrane

Status
Unknown status
Phase
Phase 4
Locations
Israel
Study Type
Interventional
Intervention
I.V cefuroxime 750 mg*3/d for 2 days
I.V ampicillin 2 gram x4/d for 2 days
P.O cefuroxime 500 mgx2/d for 5 days
P.O roxithromycin 150 mg*2/d for 7 days
P.O moxypen 500 mgx3/d for 5 days
Sponsored by
Western Galilee Hospital-Nahariya
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Premature Rupture of Membrane focused on measuring early-onset neonatal sepsis, Prophylactic antibiotics, Pregnancy, PPROM, EOS

Eligibility Criteria

18 Years - 45 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Women with PPROM between 24+0 and 34+0 weeks of gestation who are suitable for conservative management

Exclusion Criteria:

  • P-PROM>34 weeks of gestation
  • Suspected fetal distress or chorioamnionitis
  • Active labor
  • Drug allergy to one of the study regiments
  • Immune deficiency
  • Multiple pregnancy

Sites / Locations

  • Galil Medical CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

cefuroxime

ampicillin

Arm Description

I.V cefuroxime 750 mg*3/d for 2days followed by P.O cefuroxime 500 mgx2/d in addition to P.O roxithromycin 150 mg*2/d for 7 days

I.V ampicillin 2 gram x4/d for 2 days followed by P.O moxypen 500 mgx3/d for 5 days in addition to P.O roxithromycin 150 mg*2/d for 7 days

Outcomes

Primary Outcome Measures

EARLY NEONATAL SEPSIS - positive blood culture
Number of Participants with early neonatal sepsis
latency period
time in days
Chorioamnionitis rate
rate of positive cultures

Secondary Outcome Measures

Neonatal weight
grams
Apgar score
score from 0 to 10

Full Information

First Posted
June 2, 2016
Last Updated
December 28, 2016
Sponsor
Western Galilee Hospital-Nahariya
search

1. Study Identification

Unique Protocol Identification Number
NCT02819570
Brief Title
Comparison of Two Antibiotic Prophylactic Protocols in Preterm Premature Rupture of the Membranes
Official Title
Comparison of Two Antibiotic Prophylactic Protocols in Preterm Premature Rupture of the Membranes. A Randomized Prospective, Open Trial
Study Type
Interventional

2. Study Status

Record Verification Date
December 2016
Overall Recruitment Status
Unknown status
Study Start Date
November 2015 (undefined)
Primary Completion Date
December 2017 (Anticipated)
Study Completion Date
December 2017 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Western Galilee Hospital-Nahariya

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The objective of the study is to compare a new antibiotic protocol with the current prophylactic treatment in routine use and to evaluate obstetric and neonatal outcome: preterm labor, chorioamnionitis and early onset sepsis
Detailed Description
Preterm premature rupture of membranes (PPROM) occurs in approximately 3% of all pregnancies and is associated with approximately one-third of preterm births. The incidence of chorioamnionitis in women with premature rupture of membranes (PROM) at < 27, 28 to 36, and > 37weeks' gestation is 41, 15, and 2%, respectively. Intra-amniotic infection is usually polymicrobial, comprised vaginal or enteric flora including aerobic and anaerobic bacteria and atypical agents, such as Mycoplasma. Group B streptococcus (GBS) has been a frequent pathogen. The American College of Obstetricians and Gynecologists approach to PPROM consists of recommending induction of labor in all women > 34 weeks' gestation. In the absence of intrauterine infection, placental abruption or non-reassuring fetal heart rate, management of women with PPROM < 34 weeks consists of hospitalization from the time of diagnosis until delivery, administration of antenatal corticosteroids, and a 7-day course of antibiotic prophylactic therapy to prolong the latency period. Antibiotic therapy has been associated with significant reductions in chorioamnionitis, deliveries within 48 hours, and early-onset (within 3 days of delivery) neonatal sepsis (EOS). The antibiotic regimen in PPROM usually consists of ampicillin intravenously for 48 hours, followed by oral amoxicillin for 5 days (specifically targeting GBS), and a macrolide targeting atypical agents. An increase in EOS due to gram negative Enterobacteriaceae have been reported lately with a relative decrease in GBS related EOS . These data may have an impact on the antibiotic regimen used for PPROM. The Local pathogens distribution in cases of EOS and their antibiotic sensitivity profiles in Northern Israel have been explored in a multicenter study There were 27 neonates diagnosed with EOS with positive blood cultures. Aerobic Enterobacteriaceae accounted for 14 cases (52%) and group B streptococcus for 7 cases (26%). Of the Escherichia coli and Klebsiella sp.,only 38% were sensitive to ampicillin. As a result the most effective antibiotic protocol to cover those pathogens is required. The purpose of the current study is to compare a new antibiotic protocol with the current prophylactic treatment in use and to evaluate pregnancy and neonatal outcome. The diagnosis of preterm premature rupture of membranes (PPROM) is clinical, and is based on visualization of amniotic fluid in the vagina of a woman who presents with a history of leaking fluid. Laboratory tests as "Amniosure" can be used to confirm the clinical diagnosis when it is uncertain. Women who meet the study criteria and have signed inform consent will be randomly divided in two groups to receive prophylactic antibiotic treatment as follow: I.V ampicillin 2 gram x4/d for 2 days followed by P.O moxypen 500 mgx3/d for additional 5 days+ P.O roxithromycin 150 mg*2/d for 7 days I.V cefuroxime 750 mg*3/d for 2days followed by P.O cefuroxime 500 mgx2/d + P.O roxithromycin 150 mg*2/d for 7 days A course of corticosteroids will be given to all women participating in the study Expectant management: Vital signs *3/day Uterine tenderness evaluation Complete Blood Count + C-reactive protein every second day Urine culture and GBS recto-vaginal swab Fetal heart monitoring*6 /d Sonography evaluation every 2-3 days Vaginal swab once a week Fetal movements follow up Labor induction will be conducted at 34 weeks of gestation If chorioamnionitis is suspected amniocentesis should be considered or expeditious delivery

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Premature Rupture of Membrane
Keywords
early-onset neonatal sepsis, Prophylactic antibiotics, Pregnancy, PPROM, EOS

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
400 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
cefuroxime
Arm Type
Experimental
Arm Description
I.V cefuroxime 750 mg*3/d for 2days followed by P.O cefuroxime 500 mgx2/d in addition to P.O roxithromycin 150 mg*2/d for 7 days
Arm Title
ampicillin
Arm Type
Active Comparator
Arm Description
I.V ampicillin 2 gram x4/d for 2 days followed by P.O moxypen 500 mgx3/d for 5 days in addition to P.O roxithromycin 150 mg*2/d for 7 days
Intervention Type
Drug
Intervention Name(s)
I.V cefuroxime 750 mg*3/d for 2 days
Intervention Type
Drug
Intervention Name(s)
I.V ampicillin 2 gram x4/d for 2 days
Intervention Type
Drug
Intervention Name(s)
P.O cefuroxime 500 mgx2/d for 5 days
Intervention Type
Drug
Intervention Name(s)
P.O roxithromycin 150 mg*2/d for 7 days
Intervention Type
Drug
Intervention Name(s)
P.O moxypen 500 mgx3/d for 5 days
Primary Outcome Measure Information:
Title
EARLY NEONATAL SEPSIS - positive blood culture
Description
Number of Participants with early neonatal sepsis
Time Frame
within 3 days of delivery
Title
latency period
Description
time in days
Time Frame
from date of randomization until the date of delivery assessed up to 10 weeks
Title
Chorioamnionitis rate
Description
rate of positive cultures
Time Frame
from day of randomization until date of clinical/laboratory chorioamnionitis diagnosis assessed up to 10 weeks
Secondary Outcome Measure Information:
Title
Neonatal weight
Description
grams
Time Frame
at delivery
Title
Apgar score
Description
score from 0 to 10
Time Frame
1 minute 5 minute
Other Pre-specified Outcome Measures:
Title
Number of participants with adverse events as assessed by umbilical cord acid-based analysis<7
Description
cord ph analysis at delivery (units of moles per liter)
Time Frame
at delivery
Title
Neonatal intensive care unit (NICU) admission duration
Description
days from admission until rerelease from NICU assessed up to 6 month
Time Frame
days since delivery until rerelease from NICU, assessed up to 6 month

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Women with PPROM between 24+0 and 34+0 weeks of gestation who are suitable for conservative management Exclusion Criteria: P-PROM>34 weeks of gestation Suspected fetal distress or chorioamnionitis Active labor Drug allergy to one of the study regiments Immune deficiency Multiple pregnancy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Maya Wolf, MD
Phone
972-507887800
Email
homesickid@yahoo.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Maya Wolf, MD
Organizational Affiliation
1Department of Obstetrics & Gynecology, Galilee Medical Center, 2Faculty of Medicine in the Galilee, Bar Ilan University, Nahariya, Israel
Official's Role
Principal Investigator
Facility Information:
Facility Name
Galil Medical Center
City
Nahariyya
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maya Wolf, MD
Phone
972-507887800
Email
homesickid@yahoo.com

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
16125041
Citation
Mercer BM. Preterm premature rupture of the membranes: current approaches to evaluation and management. Obstet Gynecol Clin North Am. 2005 Sep;32(3):411-28. doi: 10.1016/j.ogc.2005.03.003.
Results Reference
background
PubMed Identifier
8293582
Citation
Newton ER. Chorioamnionitis and intraamniotic infection. Clin Obstet Gynecol. 1993 Dec;36(4):795-808. doi: 10.1097/00003081-199312000-00004.
Results Reference
background
PubMed Identifier
3335795
Citation
Sperling RS, Newton E, Gibbs RS. Intraamniotic infection in low-birth-weight infants. J Infect Dis. 1988 Jan;157(1):113-7. doi: 10.1093/infdis/157.1.113.
Results Reference
background
PubMed Identifier
24084566
Citation
Practice bulletins No. 139: premature rupture of membranes. Obstet Gynecol. 2013 Oct;122(4):918-930. doi: 10.1097/01.AOG.0000435415.21944.8f.
Results Reference
background
PubMed Identifier
8416463
Citation
Carlan SJ, O'Brien WF, Parsons MT, Lense JJ. Preterm premature rupture of membranes: a randomized study of home versus hospital management. Obstet Gynecol. 1993 Jan;81(1):61-4.
Results Reference
background
PubMed Identifier
15064028
Citation
Turnbull DA, Wilkinson C, Gerard K, Shanahan M, Ryan P, Griffith EC, Kruzins G, Stamp GE. Clinical, psychosocial, and economic effects of antenatal day care for three medical complications of pregnancy: a randomised controlled trial of 395 women. Lancet. 2004 Apr 3;363(9415):1104-9. doi: 10.1016/S0140-6736(04)15893-5.
Results Reference
background
PubMed Identifier
16856047
Citation
Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD004454. doi: 10.1002/14651858.CD004454.pub2.
Results Reference
background
PubMed Identifier
11174492
Citation
Harding JE, Pang J, Knight DB, Liggins GC. Do antenatal corticosteroids help in the setting of preterm rupture of membranes? Am J Obstet Gynecol. 2001 Jan;184(2):131-9. doi: 10.1067/mob.2001.108331.
Results Reference
background
PubMed Identifier
24297389
Citation
Kenyon S, Boulvain M, Neilson JP. Antibiotics for preterm rupture of membranes. Cochrane Database Syst Rev. 2013 Dec 2;(12):CD001058. doi: 10.1002/14651858.CD001058.pub3.
Results Reference
background
PubMed Identifier
9307346
Citation
Mercer BM, Miodovnik M, Thurnau GR, Goldenberg RL, Das AF, Ramsey RD, Rabello YA, Meis PJ, Moawad AH, Iams JD, Van Dorsten JP, Paul RH, Bottoms SF, Merenstein G, Thom EA, Roberts JM, McNellis D. Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes. A randomized controlled trial. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. JAMA. 1997 Sep 24;278(12):989-95.
Results Reference
background
PubMed Identifier
21160459
Citation
Workowski KA, Berman S; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 2010 Dec 17;59(RR-12):1-110. Erratum In: MMWR Recomm Rep. 2011 Jan 14;60(1):18. Dosage error in article text.
Results Reference
background
PubMed Identifier
23111115
Citation
Grigsby PL, Novy MJ, Sadowsky DW, Morgan TK, Long M, Acosta E, Duffy LB, Waites KB. Maternal azithromycin therapy for Ureaplasma intraamniotic infection delays preterm delivery and reduces fetal lung injury in a primate model. Am J Obstet Gynecol. 2012 Dec;207(6):475.e1-475.e14. doi: 10.1016/j.ajog.2012.10.871. Epub 2012 Oct 23.
Results Reference
background
PubMed Identifier
26023907
Citation
Wolf MF, Miron D, Peleg D, Rechnitzer H, Portnov I, Salim R, Keness Y, Reich D, Ami MB, Peretz A, Koshnir A, Shachar IB. Reconsidering the Current Preterm Premature Rupture of Membranes Antibiotic Prophylactic Protocol. Am J Perinatol. 2015 Nov;32(13):1247-50. doi: 10.1055/s-0035-1552935. Epub 2015 May 29.
Results Reference
background
PubMed Identifier
32407901
Citation
Wolf MF, Sgayer I, Miron D, Krencel A, Sheffer VF, Idriss SS, Sammour RN, Peleg D, Shachar IB, Rechnitzer H, Bornstein J. A novel extended prophylactic antibiotic regimen in preterm pre-labor rupture of membranes: A randomized trial. Int J Infect Dis. 2020 Jul;96:254-259. doi: 10.1016/j.ijid.2020.05.005. Epub 2020 May 11.
Results Reference
derived

Learn more about this trial

Comparison of Two Antibiotic Prophylactic Protocols in Preterm Premature Rupture of the Membranes

We'll reach out to this number within 24 hrs